MYLAN N V's ticker is MYL and the CUSIP is N59465109. A total of 599 filers reported holding MYLAN N V in Q3 2015. The put-call ratio across all filers is 0.74 and the average weighting 0.4%.
About MYLAN N V
Mylan N.V. is a global pharmaceutical company that specializes in the development, manufacturing, and distribution of generic and branded drugs. The company has a presence in more than 165 countries and has a portfolio of over 7,500 products. Mylan's mission is to provide access to high-quality medicine to people around the world.
Mylan has been in the news recently due to its acquisition by Pfizer's Upjohn unit. The deal is expected to close in the second half of 2020, and it will create a new company that will be one of the largest pharmaceutical companies in the world. The new company will be called Viatris, and it will have a portfolio of more than 20,000 products.
Mylan has been a leader in the generic drug market for many years. The company has a strong pipeline of products, and it is constantly working to develop new drugs that can help people around the world. Mylan's focus on innovation has helped it to become one of the most successful pharmaceutical companies in the world.
In conclusion, Mylan N.V. is a global pharmaceutical company that is committed to providing access to high-quality medicine to people around the world. The company's focus on innovation and its strong pipeline of products make it a leader in the generic drug market. With its acquisition by Pfizer's Upjohn unit, Mylan is poised to become an even stronger player in the pharmaceutical industry.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $7,000 | -99.2% | 500 | -98.4% | 0.00% | -99.3% |
| Q1 2019 | $862,000 | -4.8% | 30,399 | -8.0% | 0.55% | -9.9% |
| Q4 2018 | $905,000 | -42.1% | 33,034 | -22.7% | 0.61% | -39.8% |
| Q3 2018 | $1,563,000 | -0.6% | 42,717 | -1.8% | 1.01% | -0.3% |
| Q2 2018 | $1,573,000 | -30.9% | 43,517 | -21.4% | 1.01% | -32.4% |
| Q1 2018 | $2,278,000 | -50.8% | 55,337 | -49.5% | 1.49% | -0.9% |
| Q4 2017 | $4,634,000 | +151.7% | 109,518 | +86.6% | 1.51% | +33.0% |
| Q3 2017 | $1,841,000 | -19.5% | 58,688 | -0.4% | 1.13% | -27.2% |
| Q2 2017 | $2,288,000 | -2.5% | 58,939 | -2.1% | 1.56% | -6.9% |
| Q1 2017 | $2,347,000 | +4.9% | 60,204 | +2.7% | 1.67% | +0.2% |
| Q4 2016 | $2,237,000 | -4.5% | 58,639 | -4.6% | 1.67% | -10.2% |
| Q3 2016 | $2,343,000 | -10.6% | 61,452 | +1.4% | 1.86% | -12.7% |
| Q2 2016 | $2,620,000 | -3.4% | 60,597 | +3.6% | 2.13% | +1.0% |
| Q1 2016 | $2,712,000 | -7.2% | 58,507 | +8.3% | 2.11% | -13.6% |
| Q4 2015 | $2,921,000 | +34.7% | 54,019 | +0.3% | 2.44% | +33.7% |
| Q3 2015 | $2,169,000 | – | 53,884 | – | 1.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paulson & Co. | 22,028,061 | $952,493,000 | 9.68% |
| Nebula Capital Management, LP | 27,215 | $1,177,000 | 9.32% |
| Litespeed Management, L.L.C. | 1,094,363 | $47,320,000 | 9.17% |
| Migdal Insurance & Financial Holdings Ltd. | 6,043,200 | $261,308,000 | 7.22% |
| Mivtachim The Workers Social Insurance Fund Ltd. (Under Special Management) | 1,955,000 | $84,535,000 | 6.97% |
| Hengistbury Investment Partners LLP | 790,049 | $34,162,000 | 6.79% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,666,798 | $115,312,000 | 6.52% |
| NORTH TIDE CAPITAL, LLC | 1,250,000 | $54,050,000 | 6.02% |
| Camber Capital Management LP | 2,740,000 | $118,478,000 | 5.73% |
| NEXTHERA CAPITAL LP | 140,000 | $6,054,000 | 5.24% |